Sofía Pereira Gallardo

Suggest Changes
Learn More
Recurrent or metastatic GISTs are currently treated with kinase inhibitors since they achieves disease control in 70–85% of patients but this response depend on KIT and PDGFRA gene mutation status.(More)
Gastrointestinal stromal tumors (GISTs) are generally CD117-positive and KIT or PDGFRA mutation-driven mesenchymal tumors of the gastrointestinal tract, probably originating in interstitial cells of(More)
  • 1